|
Office of the Director
The Director of DPMCDA, David McCann, Ph.D., provides leadership and direction to the varied activities of the Division’s programs. He is assisted in this endeavor by staff who coordinate the functional areas of the OD, DPMCDA. The Informatics Unit, residing in the OD, DPMCDA, designs, develops, integrates, supports, and provides information technology tools, customized applications, informatics support, bio-informatics programs, and support for scientific computing. The functional areas within the OD, DPMCDA provide policy and technology transfer guidance, program development and evaluation, and overall operational, administrative, and budgeting coordination for the Division. The OD, DPMCDA works closely with the OD, NIDA in establishing relationships with other Government agencies and health organizations, Congress, academia, and the private sector.
Office of the Director Personnel Contacts
David J. McCann. Ph.D., Director (acting)
301-443-6173
dmccann@nih.gov
Provides leadership, programmatic oversight, and direction for all DPMCDA projects. Manages resources involved in the development of immunological and pharmacological approaches for the treatment of psychoactive substance disorders, with an emphasis on cocaine, methamphetamine and cannabis dependence disorders. Received a B.S. in Pharmacy from the Albany College of Pharmacy in 1981 and his Ph.D. from the Department of Pharmacology and Therapeutics, SUNY Buffalo in 1988. After serving as a Staff Fellow and then a Senior Staff Fellow at the NIDA Intramural Research Program, joined the Medications Development Program in 1992.
Ivan Montoya, M.P.H., M.D., Deputy Director (acting)
301-443-8639
imontoya@nih.gov
Dr. Montoya is a psychiatrist and epidemiologist who specialize in the public health aspects and the development of medications for the treatment of substance-related disorders (SRDs). In conjunction with the Division Director, he provides programmatic oversight for grants and contracts in DPMCDA, and manages activities and resources of the Division involved in the development of medications for the treatment of SRDs. He also serves as Medical Monitor and provides medical oversight to grants and contracts, as well as supports NIDA’s implementation of NIH wide policies for data and safety monitoring of clinical trials. He leads NIDA’s marijuana medications development iniative. He collaborates with the IRP in research projects, with the NIDA’s International Office in the Latin American Initiative, and is member of several scientific interest workgroups. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. He joined NIDA in December 1999.
James Glass, M.S., Chief, Informatics Program
301-443-1112
jg96y@nih.gov
Formulates and manages an informatics program supporting discovery, clinical, and regulatory programs. Thirty-nine years of experience in drug abuse treatment and prevention field, the past twenty-eight years with NIDA. Joined DTR&D in 1993.
Aida M. Klun, M.B.A., Program Analyst and Technology Transfer Coordinator
301-443-1122
ak102w@nih.gov
Plans, coordinates, and executes the administrative and managerial aspects of the Division. Assists the Director, DPMCDA with special research and analysis projects, personnel management, project management and strategic planning, procurement, space and property management, special events, presentations, special projects, operations and clinical trial budgets, technology transfer and other business-related interactions with private industry and academia, in support of divisional planning and evaluation activities. Joined DPMCDA in 1997.
Office of the Director
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Boulevard
Room 4123, MSC 9551
Bethesda, MD 20892-9551
(301) 443-6173 (phone)
(301) 443-2599 (fax)
|
|
DPMCDA Index
About NIDA Contents
|
|
